Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout latin America and the caribbean

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 615-623

  Tuboi, Suely H ^a   Schechter, Mauro ^a   McGowan, Catherine C ^b   Cesar, Carina ^c   Krolewiecki, Alejandro ^c   Cahn, Pedro ^c   Wolff, Marcelo ^d   Pape, Jean W ^e   Padgett, Denis ^f   Madero, Juan Sierra ^g   Gotuzzo, Eduardo ^h   Masys, Daniel R ^b   Shepherd, Bryan E ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d UNIVERSITY OF CHILE   (Chile)

^e Les Centres GHESKIO   (United States)

^f NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^g INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^h INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

Author keywords

Antiretroviral therapy; Caribbean; Cohort; Highly active; HIV; Low income population; South America; Treatment outcome

Indexed keywords

HEMOGLOBIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARGENTINA; ARTICLE; BRAZIL; CD4 LYMPHOCYTE COUNT; CHILE; DEMOGRAPHY; FEMALE; FOLLOW UP; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HONDURAS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KAPLAN MEIER METHOD; LOWEST INCOME GROUP; MAJOR CLINICAL STUDY; MALE; MEXICO; MORTALITY; PERU; PRIORITY JOURNAL; PROGNOSIS; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; VIRUS LOAD;

EID: 68449100517     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181a44f0a     Document Type: Article

References (39)

1. UNAIDS. AIDS Epidemic Update, December 2007. Geneva, Switzerland: WHO; 2007. Available at http://www.unaids.org/en/HTV-data/2007EpiUpdate/default. asp. Accessed December 14, 2007.
2. WHO. Towards Universal Access Progress Report. Scaling up Priority HIV/AIDS Interventions in the Health Sector. Geneva, Switzerland: WHO; 2007. Available at: http://www.who.int/hiv/mediacentre/universal-access-progress- report-en.pdf. Accessed December 12, 2007.
3. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
4. Zhou J, Kumarasamy N, Ditangco R, et al. The TREAT Asia HIV observational database: baseline and retrospective data. J Acquir Immune Defic Syndr. 2005;38:174-179.
5. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
6. McGowan CC, Cahn P, Gotuzzo E, et al. Cohort profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol. 2007;36:969-976.
7. Shafer JL. Analysis of Incomplete Multivariate Data. London, United Kingdom: Chapman & Hall; 1997.
8. Harrell FEJ. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: Springer; 2001.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
10. Smith-Warner SA, Spiegelman D, Ritz J, et al. Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol. 2006;163:1053-1064.
11. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779-788.
12. Louis C, Ivers LC, Smith Fawzi MC, et al. Late presentation for HIV care in central Haiti: factors limiting access to care. AIDS Care. 2007;19:487-491.
13. Infante C, Zarco A, Cuadra SM, et al. HIV/AIDS-related stigma and discrimination: the case of health care providers in Mexico [in Spanish]. Salud Publica Mex. 2006;48:141-150.
14. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334.
15. Wolff MJ, Beltran CJ, Vasquez P, et al. The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country - organization and preliminary results. J Acquir Immune Defic Syndr. 2005;40:551-557.
16. Echevarria J, Lopez de Castilla D, Seas C, et al. Scaling-up highly active antiretroviral therapy (HAART) in Peru: problems on the horizon. J Acquir Immune Defic Syndr. 2006;43:625-626.
17. Sebastian JL, Munoz M, Palacios E, et al. Scaling up HIV treatment in Peru: applying lessons from DOTS-Plus. J Int Assoc Physicians AIDS Care (Chic Ill). 2006;5:137-142.
18. PAHO. Health situation in the Americas. In: Health Surveillance, Disease Prevention and Control, ed: World Health Organization, 2008. Washington, D.C.
19. Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med. 2004;351:23-32.
20. Fawzi W, Msamanga G, Spiegelman D, et al. Studies of vitamins and minerals and HIV transmission and disease progression. J Nutr. 2005;135:938-944.
21. Mehta S, Fawzi W Effects of vitamins, including vitamin A, on HIV/AIDS patients. Vitam Horm. 2007;75:355-383.
22. Paton NI, Sangeetha S, Earnest A, et al. The impact of malnutrition on survival and the CD4 count response in HIV-infected patients starting antiretroviral therapy. HIV Med. 2006;7:323-330.
23. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
24. Moh R, Danel C, Messou E, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS. 2007;21:2483-2491.
25. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52.
26. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770-776.
27. Zachariah R, Fitzgerald M, Massaquoi M, et al. Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi. AIDS. 2006;20:2355-2360.
28. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ. 2008;86:559-567.
29. Wood E, Montaner JS, Chan K, et al. Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996. AIDS. 2002;16:2065-2072.
30. Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139:810-816.
31. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16:1051-1058.
32. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006;3:e438.
33. Hofer CB, Schechter M, Harrison LH. Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2004;36:967-971.
34. Delpierre C, Dray-Spira R, Cuzin L, et al. Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS. 2007;18:312-317.
35. Girardi E, Aloisi MS, Arid C, et al. Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy. J Acquir Immune Defic Syndr. 2004;36:951-959.
36. Sabin CA, Smith CJ, Gumley H, et al. Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy. AIDS. 2004;18:2145-2151.
37. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004;5:93-98.
38. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20:1447-1450.
39. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV J Acquir Immune Defic Syndr. 2005;40:96-101.